| Mark Hamming, | |
|
350 S Greenleaf St, Suite 405, Gurnee, IL 60031-5709 | |
| (847) 336-3335 | |
| Not Available |
| Full Name | Mark Hamming |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 16 Years |
| Location | 350 S Greenleaf St, Gurnee, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861653453 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 036-136089 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspire Home Healthcare, Llc | Morton grove, IL | Home health agency |
| Northwestern Lake Forest Hospital | Lake forest, IL | Hospital |
| Advocate Condell Medical Center | Libertyville, IL | Hospital |
| Vista Medical Center East | Waukegan, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Healthcare Services Inc | 2163339722 | 2654 |
| Illinois Bone And Joint Institute Llc | 6002814878 | 519 |
News Archive
Lung cancer is the second most common type of cancer and leading cause of cancer death in men and women, with non-small cell lung cancer (NSCLC) accounting for up to 90% of cases. Somatic mutations heavily impact the sensitivity of NSCLC patients to various drug treatments, and are critical for choosing the most effective targeted therapies for this cancer.
Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.
A study in the Proceedings of the National Academy of Sciences shows that some forms of the single celled parasites, Trypanosoma brucei and Toxoplasma gondii behave like cancer cells.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
› Verified 9 days ago
| Entity Name | Illinois Bone And Joint Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205922432 PECOS PAC ID: 6002814878 Enrollment ID: O20061110000331 |
News Archive
Lung cancer is the second most common type of cancer and leading cause of cancer death in men and women, with non-small cell lung cancer (NSCLC) accounting for up to 90% of cases. Somatic mutations heavily impact the sensitivity of NSCLC patients to various drug treatments, and are critical for choosing the most effective targeted therapies for this cancer.
Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.
A study in the Proceedings of the National Academy of Sciences shows that some forms of the single celled parasites, Trypanosoma brucei and Toxoplasma gondii behave like cancer cells.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Hamming, 900 Rand Rd, Suite 300, Des Plaines, IL 60016-2359 Ph: (847) 324-3976 | Mark Hamming, 350 S Greenleaf St, Suite 405, Gurnee, IL 60031-5709 Ph: (847) 336-3335 |
News Archive
Lung cancer is the second most common type of cancer and leading cause of cancer death in men and women, with non-small cell lung cancer (NSCLC) accounting for up to 90% of cases. Somatic mutations heavily impact the sensitivity of NSCLC patients to various drug treatments, and are critical for choosing the most effective targeted therapies for this cancer.
Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.
A study in the Proceedings of the National Academy of Sciences shows that some forms of the single celled parasites, Trypanosoma brucei and Toxoplasma gondii behave like cancer cells.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.
› Verified 9 days ago
Gerard Martin Goshgarian, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 105 N Greenleaf St, Gurnee, IL 60031 Phone: 847-244-4343 Fax: 847-244-8111 | |
Roger Barrett Collins, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 N Greenleaf St, Gurnee, IL 60031 Phone: 847-623-3090 Fax: 847-623-9620 | |
Tomas Nemickas, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 350 S Greenleaf St, Suite 405, Gurnee, IL 60031 Phone: 847-336-3335 | |
Bruce Summerville, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 350 S Greenleaf St, Suite 405, Gurnee, IL 60031 Phone: 847-336-3335 | |
John Gottfried Mayer, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 N Greenleaf St, Gurnee, IL 60031 Phone: 847-623-3090 Fax: 847-623-9620 | |
Serafin Deleon, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 350 S Greenleaf St, Suite 405, Gurnee, IL 60031 Phone: 847-336-3335 | |
Edward Logue, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 350 S Greenleaf St, Suite 405, Gurnee, IL 60031 Phone: 847-336-3335 |